Enhancing Consumer Protection Through the Drugs and Cosmetics Act

Every time you buy a medicine from a pharmacy or pick up a cosmetic product, you’re placing a certain level of trust in the system – trust that what’s on the label matches what’s inside the package, that the product is safe, and that someone is watching out for your interests. In India, that “someone” is primarily the Drugs and Cosmetics Act, 1940 – a law that has evolved significantly over the decades to become one of the most important instruments of consumer protection in the pharmaceutical and cosmetic sectors.

A law that grew with the times 🔗

The Drugs and Cosmetics Act was originally enacted in 1940 to regulate the import, manufacture, distribution, and sale of drugs and cosmetics across India. Its primary goal was straightforward: ensure that products available in the market are safe, effective, and meet prescribed quality standards. However, the regulatory landscape in India looked very different in 1940 than it does today. Over the decades, the Act underwent a series of significant amendments – in 1955, 1962, 1982, 1986, 1995, and most notably in 2008 – each one strengthening the consumer protection architecture built around drugs and cosmetics.

The most consequential shift came with the enactment of the Consumer Protection Act, 1986. That legislation redefined how India approached consumer rights broadly, and its introduction prompted corresponding amendments to the Drugs and Cosmetics Act – amendments that explicitly recognised the role of consumers and their organisations in pharmaceutical quality oversight.

What changed after 1986: empowering consumers to test and challenge 🔗

One of the most practically significant provisions in the Drugs and Cosmetics Act is Section 26, which deals with the right of a purchaser to obtain a test or analysis of any drug or cosmetic they have bought. As amended post-1986, this provision goes further than merely giving an individual consumer this right. It now expressly extends the same right to recognised consumer associations – whether or not the person who purchased the product is even a member of that association.

Under Section 26, any person or recognised consumer association can apply in the prescribed manner, pay the prescribed fee, and submit a drug or cosmetic sample to a Government Analyst for testing. The explanation to the section defines a “recognised consumer association” as a voluntary consumer association registered under the Companies Act, 1956 or any other law in force. This alignment with the Consumer Protection Act’s own framework for recognised associations is deliberate – it creates a unified system where consumer organisations can operate across both statutes.

This provision is significant because it converts quality assurance from a purely government function into a participatory process. Consumer groups can independently procure samples from the market and get them tested. If results reveal that a product is substandard, misbranded, or spurious, the association can trigger legal and regulatory action – giving civil society a genuine enforcement role alongside the state.

Understanding the key offences: substandard, misbranded, and spurious 🔗

To understand what consumers are being protected against, it helps to know exactly what these three categories mean under the Act.

Substandard drugs and cosmetics 🔗

A drug or cosmetic is considered “not of standard quality” – commonly called substandard – when it fails to meet the specifications laid out in the Second Schedule of the Act or as otherwise prescribed. This could mean incorrect potency, contamination, improper packaging, or failure of stability tests. Section 18 of the Act prohibits the manufacture, sale, stocking, or distribution of any substandard drug or cosmetic. The consequences for violating this provision include imprisonment and fines, with harsher penalties if the substandard product causes harm to a consumer.

Misbranded drugs and cosmetics 🔗

A drug is deemed misbranded if it is so coloured, coated, or polished that damage is concealed, if it is not labelled in the prescribed manner, or if its label bears any false claim or misleading information. For cosmetics, misbranding includes false or deceptive descriptions of the product’s composition or effect. Sections 17 and 17C of the Act set out detailed definitions for misbranded drugs and cosmetics respectively. This is particularly relevant to everyday consumer purchases – a moisturiser claiming to contain ingredients it doesn’t actually have, or a medicine with an exaggerated therapeutic claim, falls squarely within this definition.

Spurious drugs and cosmetics 🔗

Spurious products are the most serious category. A drug is spurious if it is an imitation of another drug, bears the name of a fictitious manufacturer, has been wholly or partly substituted by another substance, or purports to be a product of a manufacturer of whom it is not truly a product. In short, spurious drugs are fakes – they deceive both the seller and the consumer about what is actually being supplied. Section 17B of the Act defines spurious drugs, and the 2008 amendment significantly tightened the legal response to them.

The 2008 amendment: sharper teeth for consumer protection 🔗

The Drugs and Cosmetics (Amendment) Act, 2008 – which came into force on 10 August 2009 – was a landmark development in the consumer protection framework under this legislation. It was driven largely by the recommendations of an Expert Committee constituted in 2003 under the chairmanship of Dr. R.A. Mashelkar, which had flagged the widespread problem of spurious and adulterated drugs in India and the inadequacy of existing penalties.

The amendment made several critical changes. First, it substantially enhanced penalties. Where a person uses an adulterated or spurious drug that causes death or grievous hurt to the user, the offender is now liable to imprisonment for not less than ten years, extendable to life, and a fine of not less than ten lakh rupees or three times the value of the drugs confiscated, whichever is more. These are among the most severe penalties in India’s consumer protection statute book.

Second, the amendment introduced the concept of Special Courts. Given that prosecution cases related to spurious drugs had historically lingered in the court system for years without resolution, the amendment mandated that the Central or State Government designate Courts of Session as Special Courts for speedier trials of the most serious drug-related offences – including the importation of adulterated or spurious drugs, and trading in drugs likely to cause death or grievous hurt.

Third, and importantly from a consumer standpoint, the amendment provided for compensation to victims of adulterated or spurious drugs – a provision that directly addresses the harm suffered by individual consumers rather than merely punishing manufacturers.

Fourth, serious offences relating to adulterated and spurious drugs were made cognizable and non-bailable, meaning that law enforcement officers can arrest without a warrant and bail is not a matter of right. This is a significant deterrent, reflecting how seriously the law now treats these violations.

The role of the CDSCO in enforcing consumer rights 🔗

The Central Drugs Standard Control Organisation (CDSCO), functioning under the Directorate General of Health Services and the Ministry of Health and Family Welfare, is the national regulatory authority responsible for implementing the Drugs and Cosmetics Act at the central level. State Drug Control Organisations work in parallel at the state level.

The CDSCO has issued specific guidelines for taking action against drugs declared spurious or not of standard quality, particularly in light of the enhanced penalties introduced in 2008. These guidelines classify substandard drugs into categories based on severity – with Category A covering counterfeit drugs that misrepresent their identity or contain harmful adulterants – and provide a structured response framework for state regulators. This creates a more uniform enforcement environment across India, which directly benefits consumers who might otherwise receive uneven protection depending on which state they live in.

How the Consumer Protection Act, 1986 and the Drugs and Cosmetics Act work together 🔗

The Consumer Protection Act, 1986 gave Indian consumers a dedicated forum to seek redressal for defective goods and deficient services, and it defined recognised consumer associations as voluntary associations registered under law that can file complaints on behalf of consumers – even those who are not members of the association. This institutional recognition of consumer associations under the 1986 Act created the infrastructure that was then mirrored in the Drugs and Cosmetics Act’s amendments.

The two statutes now function in a complementary manner. Under the Consumer Protection Act, a consumer can approach the District Consumer Disputes Redressal Commission for relief if they receive a substandard or misbranded drug. At the same time, under the Drugs and Cosmetics Act, they or their consumer association can submit a sample for testing to a Government Analyst and, upon receiving an adverse report, trigger prosecution against the manufacturer or seller. The Press Information Bureau has also noted that while the Drugs and Cosmetics Rules require statutory details on drug labels, the Consumer Protection Act separately guarantees the consumer’s right to be informed about quality, quantity, potency, purity, standard, and price – reinforcing the labelling obligations from a rights-based perspective.

This dual-track system – regulatory prosecution under the Drugs and Cosmetics Act and civil redressal under the Consumer Protection Act – gives consumers more avenues than either statute would provide on its own.

Challenges that remain 🔗

Despite this robust framework, implementation gaps persist. Drug testing laboratories across the country face capacity constraints, leading to delays in processing samples. There are also significant awareness gaps – most consumers do not know that they have the right to get a purchased drug or cosmetic tested, let alone how to exercise that right. Consumer associations, while empowered by law, need greater capacity and public awareness to use Section 26 of the Drugs and Cosmetics Act effectively. Staffing shortages among drug inspectors and inconsistent enforcement across states further dilute the protective potential of the legislation. These are challenges the regulatory system continues to grapple with, even as the legal framework has grown progressively stronger.

What do you think? Given that both individual consumers and recognised consumer associations have the legal right to submit drug or cosmetic samples for government testing, should there be a more active public awareness campaign about this right – and who should lead it? Also, with special courts now designated for serious drug offences under the 2008 amendment, do you think the current penalties are sufficient to deter the manufacture and sale of spurious drugs in India?

References

1. https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/Drugs-and-Cosmetics-Act/
2. https://en.wikipedia.org/wiki/Drugs_and_Cosmetics_Act,_1940
3. https://www.indiacode.nic.in/handle/123456789/1868?sam_handle=123456789/1362
4. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf
5. https://www.indiacode.nic.in/bitstream/123456789/15278/1/drug_cosmeticsa1940-23.pdf
6. https://indiankanoon.org/doc/1891720/
7. https://www.nishithdesai.com/SectionCategory/33/Pharma-Healthcare-Update/12/67/PharmaHealthcareUpdate/5761/1.html
8. https://www.legalitysimplified.com/cdsco-issues-stricter-guidelines-for-action-against-spurious-and-substandard-drugs/
9. https://www.indiacode.nic.in/bitstream/123456789/7052/1/consumer_protection_act_1986.pdf
10. https://www.pib.gov.in/PressReleasePage.aspx?PRID=1498840